ASH 2025 Expert Insights: Clinical Advances for Nonadvanced Systemic Mastocytosis

2025 American Society of Hematology Expert Insights: Clinical Advances for Nonadvanced Systemic Mastocytosis

Join Gabriela Hobbs, MD (Massachusetts General Hospital), a physician with expertise in hematologic disorders, and Aaron Gerds, MD (Editor-in-Chief, ASH Clinical News), for an expert discussion on emerging clinical data evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis.

This video serves as one installment in a multi-part series of expert conversations and study highlights from the 2025 American Society of Hematology (ASH) Annual Meeting.

Subscribe for ongoing conference coverage and perspectives from leaders at the forefront of hematology and cellular therapy.

🎤 Speaker: Gabriela Hobbs, MD, Massachusetts General Hospital
🎤 Interviewer: Aaron Gerds, MD, Editor-in-Chief, ASH Clinical News

The conversation reviews the results from the Phase II SUMMIT trial, which evaluated the selective KIT D816V inhibitor bezuclastinib in adults with indolent or smoldering systemic mastocytosis and persistent, moderate-to-severe symptoms despite supportive care. The study assessed changes in patient-reported symptom burden along with laboratory and bone marrow markers of disease activity.

Dr. Hobbs discusses the clinical relevance of the reported improvements in symptom scores and reductions in biomarkers such as serum tryptase and mast cell burden, as well as the safety profile observed in the trial. She also explores how these findings may shape future treatment approaches and research directions for patients living with nonadvanced systemic mastocytosis.

📖🔗 Read the full article: “Bezuclastinib Improves Symptoms, Biomarkers in Nonadvanced Systemic Mastocytosis” https://ashpublications.org/ashclinicalnews/news/9045/Bezuclastinib-Improves-Symptoms-Biomarkers-in
📚🔗 Want more? Discover more Hematology insights: https://focus.wiley.com/topic/amps-subject-codes/mdc0?utm_source=youtube&utm_medium=referral&utm_campaign=ash25_wly&utm_term=jain3

This discussion is intended for hematologists, oncologists, cellular therapy specialists, and clinical researchers who want expert commentary on CAR-T therapy, neurotoxicity, and evolving strategies in multiple myeloma care.

#Hematology #ASH #ASH2025 #systemicmastocytosis #NonadvancedSM #bezuclastinib

Runtime 00:04:42